Epitelyal Olmayan Over Kanserlerinde Pcna Ekspresyonu Ve Prognoza Etkileri

Öz

Amaç: PCNA kolorektal ve mesane karsinomlarında proliferasyon belirteci olarak kullanılmaktadır. Bu çalışmada, PCNA’nın non-epitelyal over tümörlerinde proliferasyon indeksi olarak kullanılabilirliği araştırılmıştır. Yöntem: Patolojik olarak non-epitelyal over kanseri tanısı alan 30 olgunun PCNA immünreaktivitesi, streptoavidin-biotin antikor kompleksi kullanılarak değerlendirilmiştir. PCNA immünreaktivitesi ve Lİ indeksi ile non-epitelyal tümörlerdeki stage, grade ve lenf nodu tutulumu arasındaki olası ilişki araştırılmıştır. Bulgular: Çalışmamıza alınan hastaların yaş ortalaması 52.6 ± 6.7, ortalama doğum sayısı 3.1±1.5 ve ortalama vücut kitle indeksleri 26.7 ± 4.2 kg/m2 olarak belirlenmiştir. Olguların % 83’ü postmenopozal, % 17’si premenopozal dönemde olduğu, % 47’sinin 5 yıldan uzun süreli sigara kullanımı öyküsü bulunduğu saptanmıştır. En sık rastlanan histolojik tipin disgerminom % 27 olduğu, klinik evrelerine göre dağılımlarının ise; stage 1, 2, 3 ve 4 için sırasıyla % 33, % 13, % 47, % 7 olduğu gözlenmiştir. Histolojik olarak % 47’si grade 3, % 33’ü grade 2 ve % 20’si grade 1 olarak belirlenmiştir. Nonepitelial over tümörlerinde klinik stage ve grade arttıkça PCNA immunureaktivitesi ve Li indeksi de parelel olarak anlamlı artış göstermiştir p0.05 . Sonuç: Non epitelial over tümörlerde klinik ve histolojik evre ile PCNA ekspresyonu arasında bir korelasyon bulunmakla beraber, tümör proliferasyonu indeksi olarak PCNA kullanımı için daha ileri çalışmalar yapılması gerekmektedir.

Anahtar Kelimeler

• Non epitelyal over tümörleri, PCNA, prognoz

Pcna Expression in Non-Epithelial Ovarian Tumors and Correlation of Prognosis

Abstract

Objective: In colorectal and bladder carcinoma PCNA is used as a proliferation marker. In this study the utility of PCNA as a proliferation index in non-epithelial ovarian tumors was examined.Method: In 30 cases diagnosed by routine pathological procedures as non-epithelial ovarian cancer, the PCNA immunoreactivity was evaluated by a streptoavidin-biotin antibody complex. The possible correlations between PCNA immunoreactivity and LI index with stage, grade and lymph node involvement in non epithelial ovarian tumors were investigated. Results: In our study, average patient age 52.6 ± 6.7 years old, average parity 3.1±1.5 and average BMI 26.7 ± 4.2 kg/m2 were determined. It was found that 83 % of the patients were at postmenopausal period and 17 % premenopausal; 47 % of patients were smoking over the five years. Most common hystological type was found as dysgerminoma 27% and clinical stage distributions were determined as stage 1 33% , stage 2 13% , stage 3 47% , stage 4 7% in all patients. Grade 1 20% , grade 2 33% and grade 3 47% were found according to histological classification.In our study, it was determined in non-epithelial ovarian tumors that as stage and grade of tumor increased, PCNA immunoreactivity and LI index were also elevated statistically p

Keywords

• Non epithelial ovarian tumors, PCNA, Prognosis

References

1. Dodd JK, Henry RJW, Tyler PP, Houghton CRS. Cervical Carcinoma: A comparison of four potential biochemical tumor markers. Gynecol Oncol 1989; 32:248.
2. Sciarra JJ, Knapp RC, Berhomitz RS. Naturel history and detection of ovarian cancer. Gynecol Obstet, 1984; 28: 1-14.
3. Yavuz H, Tezcan S, Erk A. Over karsinomları. Kadın Genital Kanserleri Kitabı, 1978; 9: 385-438.
4. Scully RE. Tumors of the ovary and mal developed gonads. Washington DC: Armed Forces Institute of Pathology, 1979; 16: 247-56.
5. Abu-rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol, 1998; 25(2): 235-42.
6. Chen LM, Berek JS. Ovarian and Fallopian Tubes, In: Haskell CM, eds. Cancer Treatment. 5 th ed. Phidelphia. WB Saunders, 2000: 928-76.
7. Imai A, Furvi T, Tamai T. Gynecologic tumors and symptoms in childhood and adolescence: 10 year experience. Gynecol Obstet, 1994; 45: 227-34.
8. Obata NH, Nakasima N, Kawai M, Nikkanua F, Mombe s, Tomeda Y. Gonadoblastoma with disgerminoma in one ovary and gonadoblastoma with disgerminoma and yolc salk tumor in the contralateral ovary in a girl with 46XY karyotype. Gynecol Oncol, 1995; 58: 124-8.

9. Arroyo JG, Harris W, Laden SA. Recurrent mixed germ cell sex cord stromal tumor of the ovary in an adult. Int J Gynecol Pathol, 1998; 17(3): 281-3.
10. Miyachi K, Fritzler MJ, Tan EN. Autoantibody to nuclear antigen in proliferatif markers. J Immunology, 1978; 121: 2228-34.
11. Ogata K, Kurki P, Celic J. Monoclonal antibodies to a nuclear protein associated DNA replication. Exp Cell Res, 1986; 168: 476-86.
12. Iachino C, Katsikoyiannis N, Dallera F. Assessment of proliferating cell nuclear antigen (PCNA) immunoreactivity in carcinomas. Patholocia, 1995; 87: 56-8.
13. Jaskulski D, Gatti C, Travali S, Calabretta B, Baserga R. Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase m RNA levels by growth factors. J Biol Chem, 1998; 263: 101-7.
14. Scott RJ, Hall PA, Haldane JS et al. A comparison of immunohistochemical markers of cell proliferating with experimentally determined growth fraction. J Pathol, 1999; 165: 173.
15. Andre F, Fiazzi K, Culline S, Droz JP, Gatineau M, Takahashi Y, Oudard S, Theadore C. Peritoneal carsinomatosis in germ cell tumor: relations with retroperitoneal lymph node dissection. Am J Clin Oncol, 2000; 23(5): 460-2.
16. Benedet JL, Bender H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology, 2000; 70(2): 209-62.
17. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classification of ovarian cancer. Med Electron Microsc, 2003; 36(1): 9-17.
18. Julian CG, Woodruff JD. The biological behavior of low grade papillary serous carcinoma of the ovary. Obstet Gynecol, 1972; 40: 860-7.
19. Genodry R, Poliakoff S, Rotmensch J, Rosenshein NB, Parmley TH, Woodruff JD. Primary papillary peritoneal neoplasia. Cancer 1988; 62: 2212-22.
20. Smith LH and Oi RH. Detection of malignant ovarian neoplasms, a review of the literature. Detection of the patient at risk, clinical, radiological and cytological detection. Obstet Gynecol Survey, 1984; 39: 313-28.
21. Snider DD, Stuart GC, Nation JG and Robertson DI. Evaluation of surgical staging in stage 1 low malignant potential ovarian tumors. Gynecol Oncol, 1991; 40: 129-32.
22. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients. Gynecol Oncol, 1996; 61(1):16-21.
23. Xue Y, Feng Y, Zhu G, Zhang X. Proliferative activity in cervical intraepithelial neoplasia and cervical carcinoma. Chin Med J (Eng), 1999; 112(4):373-5.
24. Nakano T, Enoki K, Nakashima M, Ishikawa H, Ametani Y, Ohta S, Ohkuchi A, Satake S, Kojima Y, Funamoto H, Tateno M, Miwa A. Survival in patients with clear cell carcinoma of the ovary. Gan To Kagaku Ryoho, 1998; 25(1):67-73.
25. Li JD, Li MD, Li YF, Huang X, Liu JH, Liu FY, Zhang CQ. Relationship between expressions of p53, c-erb genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma. AI Zheng, 2002; 21(3):292-6.